Veru Announces Novel Modified-Release Oral Formulation for Enobosarm
VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.
Here's How Much You Would Have Made Owning Scholar Rock Holding Stock In The Last 5 Years - Scholar Rock Holding ( NASDAQ:SRRK )
Scholar Rock Holding SRRK has outperformed the market over the past 5 years by 7.22% on an annualized basis producing an average annual return of 21.06%. Currently, Scholar Rock Holding has a market capitalization of $3.16 billion.
Why Scholar Rock Stock Wilted on Wednesday
The market was hoping the company could better contain its losses.
Scholar Rock ( SRRK ) Q2 Loss Widens 63%
Scholar Rock ( NASDAQ:SRRK ) , a late-stage biopharmaceutical company specializing in therapies for serious neuromuscular and rare diseases, released its second quarter 2025 earnings on August 6, 2025. The key news was continued preparation for the potential 2025 U.S. launch of apitegromab, its ...
Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year
On July 18, 2025, Director Jeffrey S. Flier disclosed the sale of 11,136 shares of Scholar Rock ( NASDAQ:SRRK ) in an open market transaction.Source: SEC Form 4 filing from July 18. The insider transaction occurred on July 16.How does the transaction compare to previous insider activity?This is ...
Agios Appoints Dr. Jay Backstrom to Board of Directors - Agios Pharmaceuticals ( NASDAQ:AGIO )
CAMBRIDGE, Mass., July 08, 2025 ( GLOBE NEWSWIRE ) -- Agios Pharmaceuticals, Inc. AGIO, a leader in cellular metabolism and pyruvate kinase ( PK ) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors, ...
Why Scholar Rock Shares Are Soaring Today
Shares of Scholar Rock Holding ( NASDAQ: SRRK ) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.Scholar Rock, a biopharma company, reported positive results from a phase 2 trial of its muscle-preserving weight-loss therapy.The ...
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Scholar Rock Holding ( NASDAQ:SRRK )
Apitegromab cut lean mass loss from 30% to 14.6% during tirzepatide treatment. Patients lost 85% fat and only 15% lean mass on the combination therapy. Live on Wednesday June 18: 3 Summer "Power Patterns" Are About to Trigger ( One With 90% Win Rate ) . See Them Here.
Greif Posts Upbeat Earnings, Joins Planet Labs PBC, IperionX, Owens & Minor And Other Big Stocks Moving Higher On Thursday - First Majestic Silver ( NYSE:AG ) , Dollar Tree ( NASDAQ:DLTR )
U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Thursday. Shares of Greif, Inc. GEF rose sharply during Thursday's session after the company reported better-than-expected quarterly adjusted EPS results.
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Why Scholar Rock Stock Took a Knock on Monday
Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. They get worried that significant changes could reflect instability, indecision, or both in a company's decision-making.That seemed to be ...
Why Scholar Rock Holding Stock Topped the Market Today
Biotech stock Scholar Rock ( NASDAQ: SRRK ) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds. This resulted in the stock bumping nearly 3% higher on the day. That handily beat the S&P 500 index, which itself had a good trading session with ...
Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment - Scholar Rock Holding ( NASDAQ:SRRK )
Apitegromab showed a significant motor function improvement in SMA patients, with a 3.0 odds ratio for ≥3-point HFMSE gains versus placebo. 30.4% of apitegromab-treated patients had ≥3-point HFMSE improvement versus 12.5% on placebo.
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth - Scholar Rock Holding ( NASDAQ:SRRK )
Scholar Rock expects apitegromab to reach over $2 billion in global revenue, driven by positive data and market expansion. The company plans U.S. and European marketing applications for apitegromab in Q1 2025, aiming for a 2025 launch. Get Real-Time News and Alerts for Your Portfolio
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study - Biohaven ( NYSE:BHVN ) , Scholar Rock Holding ( NASDAQ:SRRK )
On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy ( SMA ) and obesity.
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday - Archer Aviation ( NYSE:ACHR ) , BridgeBio Pharma ( NASDAQ:BBIO )
U.S. stocks were higher, with the Dow Jones index gaining more than 400 points on Monday. Shares of BridgeBio Pharma, Inc. BBIO rose sharply during Monday's session after the company announced that the FDA approved Attruby to treat adults with ATTR-CM.
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - ImmunityBio ( NASDAQ:IBRX )
As of Oct. 25, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
Should You Buy Scholar Rock Holding Corporation ( SRRK ) After Golden Cross?
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Here's Why Everybody's Talking About Scholar Rock Right Now
Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers.
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.
Nasdaq To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday - Nasdaq ( NASDAQ:NDAQ )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised Nasdaq, Inc NDAQ price target from $73 to $80.
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge - AstraZeneca ( NASDAQ:AZN ) , Arcadium Lithium ( NYSE:ALTM )
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 150 points on Monday. The Dow traded down 0.97% to 41,940.43 while the NASDAQ fell 0.89% to 17,976.85. The S&P 500 also fell, dropping, 0.77% to 5,707.03. In trading on Monday, utilities shares dipped ...
How Is The Market Feeling About Scholar Rock Holding? - Scholar Rock Holding ( NASDAQ:SRRK )
Scholar Rock Holding's SRRK short percent of float has risen 4.49% since its last report. The company recently reported that it has 16.62 million shares sold short, which is 44.92% of all regular shares that are available for trading.
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher - AstraZeneca ( NASDAQ:AZN ) , Arcadium Lithium ( NYSE:ALTM )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday. The Dow traded down 0.49% to 42,146.78 while the NASDAQ fell 0.36% to 18,073.37. The S&P 500 also fell, dropping, 0.32% to 5,732.84. In trading on Monday, consumer discretionary ...
Why Is Scholar Rock Stock Skyrocketing On Monday? - Scholar Rock Holding ( NASDAQ:SRRK )
Scholar Rock Holding SRRK stock is trading higher on Monday after the company released topline results from the Phase 3 SAPPHIRE trial of apitegromab in spinal muscular atrophy.
Pfizer, Vista Outdoor, Duckhorn Portfolio And Other Big Stocks Moving Higher On Monday - Pfizer ( NYSE:PFE )
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Monday. Shares of Pfizer Inc PFE rose during Monday's session after Starboard Value acquired a $1 billion stake in the company. Pfizer shares gained 4% to $29.70 on Monday.
US Stocks Open Lower; Dow Tumbles Over 150 Points - AstraZeneca ( NASDAQ:AZN ) , CNFinance Hldgs ( NYSE:CNF )
U.S. stocks traded lower this morning, with the Dow Jones falling more than 150 points on Monday. Following the market opening Monday, the Dow traded down 0.38% to 42,192.55 while the NASDAQ fell 0.29% to 18,085.96. The S&P 500 also fell, dropping, 0.32% to 5,732.58.
Constellation Energy, Nike, Sinclair And Other Big Stocks Moving Higher On Friday - Constellation Energy ( NASDAQ:CEG )
U.S. stocks were lower, with the Dow Jones index falling around 200 points on Friday. Shares of Constellation Energy Corporation CEG rose sharply during Friday's session after the company announced it signed a 20-year power purchase agreement with Microsoft that will help launch the Crance Clean ...
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer - Fulcrum Therapeutics ( NASDAQ:FULC )
CAMBRIDGE, Mass., Aug. 19, 2024 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( Fulcrum ) FULC, a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel ...
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
CAMBRIDGE, Mass., Aug. 19, 2024 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( Fulcrum ) ( Nasdaq: FULC ) , a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the ...
Billionaire Harvard Professor's Fortune Jumps Nearly $200 Million On News Of Eli Lilly Biotech Deal
Harvard professor Timothy Springer first made headlines in 2020 when a biotech company he had invested in-Moderna-suddenly became a household name thanks to its Covid-19 vaccines, sparking a stock rally that turned him into a billionaire.
Scholar Rock Holding Shows Rising Price Performance With Jump To 83 RS Rating
On Tuesday, Scholar Rock Holding ( SRRK ) got a positive adjustment to its Relative Strength ( RS ) Rating, from 80 to 83. X IBD's unique RS Rating measures technical performance by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price performance over the trailing 52 ...
Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst - Scholar Rock Holding ( NASDAQ:SRRK )
Raymond James has initiated coverage on Scholar Rock Holding SRRK, supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to preserve muscle loss.
Scholar Rock Holding Clears Technical Benchmark, Hitting 90-Plus RS Rating
Scholar Rock Holding ( SRRK ) had its Relative Strength ( RS ) Rating upgraded from 90 to 93 Wednesday. X This proprietary rating tracks technical performance by using a 1 ( worst ) to 99 ( best ) score that indicates how a stock's price performance over the trailing 52 weeks matches up ...
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday - Dave ( NASDAQ:DAVE ) , NIO ( NYSE:NIO ) , Riskified ( NYSE:RSKD )
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. Shares of NIO Inc. NIO rose during Tuesday's session following upbeat quarterly results. NIO reported fourth-quarter revenue of 17.10 billion yuan ( $2.41 billion ) , up by 6.5% year-over-year and down by ...
Ozempic's Muscle-Loss Problem
The newest and much-hyped obesity drugs are, at their core, powerful appetite suppressants. When you eat fewer calories than you burn, the body starts scavenging itself, breaking down fat, of course, but also muscle. About a quarter to a third of the weight shed is lean body mass, and most of ...
Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation ( SRRK ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 99.1% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside ...
Firm To Present Trial Results Update at SITC Meeting
November 3, 2023 ( Investorideas.com Newswire ) Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report.
Here's Why 'Trend' Investors Would Love Betting on Scholar Rock Holding Corporation ( SRRK )
If you are looking for stocks that are well positioned to maintain their recent uptrend, Scholar Rock Holding Corporation (SRRK) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
General Dynamics, Microsoft, Waste Management And Other Big Stocks Moving Higher On Wednesday - Anavex Life Sciences ( NASDAQ:AVXL ) , Deutsche Bank ( NYSE:DB )
U.S. stocks traded lower, with the Nasdaq Composite falling more than 1% on Wednesday. Here are some big stocks recording gains in today's session. Scholar Rock Holding Corporation SRRK shares jumped 16.5% to $8.92. Jefferies upgraded Scholar Rock from Hold to Buy and announced a $20 price target.
All You Need to Know About Scholar Rock Holding Corporation ( SRRK ) Rating Upgrade to Strong Buy
Scholar Rock Holding Corporation (SRRK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
10% Owner of Scholar Rock Holding Purchased $15.00M In Stock - Scholar Rock Holding ( NASDAQ:SRRK )
Samsara BioCapital GP LLC, 10% Owner at Scholar Rock Holding SRRK, reported a large insider buy on October 18, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that LLC purchased 2,189,781 shares of Scholar Rock ...
Scholar Rock Holding Insider Trades Send a Signal - Scholar Rock Holding ( NASDAQ:SRRK )
Srinivas Akkaraju, Board Member at Scholar Rock Holding SRRK, reported a large insider buy on October 18, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Akkaraju purchased 2,189,781 shares of Scholar Rock ...
Wall Street Analysts Think Scholar Rock Holding Corporation ( SRRK ) Could Surge 203.99%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 204% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside ...
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.
Over $15M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying - Asana ( NYSE:ASAN ) , Howard Hughes Holdings ( NYSE:HHH )
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Scholar Rock ( SRRK ) Up on Pipeline Advancement, Stock Offering
Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.
Why Scholar Rock Holding Stock Soared Today
The market celebrated Scholar Rock's upsized stock offering and plans to advance development of a new obesity treatment. Here's what investors need to know.
Domino's, Walgreens, Fastenal And Other Big Stocks Moving Higher On Thursday - Ambrx Biopharma ( NASDAQ:AMAM ) , Cerevel Therapeutics Hldg ( NASDAQ:CERE )
U.S. stocks traded mixed, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today's session. LL Flooring Holdings, Inc. LL surged 35% to $3.98. Live Ventures submitted a proposal to acquire LL Flooring for $5.85 per share in cash.
NuScale Power, Stagwell And Other Big Stocks Moving Higher On Friday - Clearway Energy ( NYSE:CWEN ) , Amneal Pharmaceuticals ( NYSE:AMRX )
U.S. stocks traded higher, with the Nasdaq Composite gaining around 50 points on Friday. Here are some big stocks recording gains in Friday's session. TROOPS, Inc. TROO shares surged 14.9% to $4.4250.
